Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Is Second Big Pharma To Join Optum Labs Research Collaborative

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck follows Pfizer in signing on to the research collaborative affiliated with insurer UnitedHealth. Research underway or already completed through the collaborative includes a comparison of diabetes drugs and an effort to replicate results of the NIH-sponsored ACCORD trial on cholesterol treatments.

You may also be interested in...



Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.

FDA’s Real-World Evidence Project Finds That Pragmatic Clinical Trials Are Easier To DUPLICATE

Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.

Preapproval Information Exchange Between Sponsors, Insurers Clarified In House User Fee Bill

By codifying FDA guidance, pending legislation aims to encourage industry to become more comfortable with even unsolicited communications to payers about investigational drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel